A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Finding Study of SC411 in Children With Sickle Cell Disease
Phase of Trial: Phase II
Latest Information Update: 01 Nov 2017
At a glance
- Drugs Docosahexaenoic acid (Primary) ; Soya oil emulsion
- Indications Sickle cell anaemia
- Focus Therapeutic Use
- Acronyms SCOT
- Sponsors Sancilio & Company
- 01 Nov 2017 Primary endpoint has been met. (Change from baseline in the blood cells omega-3 fatty acids index),according to Sancilio Pharmaceuticals media release.
- 01 Nov 2017 Topline results published in a Sancilio Pharmaceuticals media release.
- 03 Oct 2017 Planned End Date changed from 1 Aug 2017 to 1 Oct 2018.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History